Home Inherited Disease and Carrier Screening Hemoglobinopathy Carrier Screening Test: Sickle Cell Disease, Thalassemia, and Results

Hemoglobinopathy Carrier Screening Test: Sickle Cell Disease, Thalassemia, and Results

By
Vita Library
-
41
Learn how hemoglobinopathy carrier screening identifies sickle cell trait, alpha- and beta-thalassemia, partner risk, confusing patterns, and pregnancy options.

Hemoglobinopathy carrier screening checks for inherited changes that alter hemoglobin, the protein in red blood cells that carries oxygen. It can identify sickle cell trait, beta-thalassemia trait, alpha-thalassemia carrier states, and other hemoglobin variants before or during pregnancy. The workup is broader than a single DNA test. A complete blood count and red-cell indices show whether cells are unusually small; hemoglobin analysis measures forms such as HbA, HbA2, HbF, HbS, HbC, and HbE; and molecular testing can clarify variants or deletions that blood testing cannot fully resolve. Correct interpretation matters because one person may carry more than one trait, iron deficiency can mimic thalassemia, transfusion can distort hemoglobin percentages, and alpha-globin gene arrangement changes fetal risk. A carrier is usually healthy, but a reproductive partner’s result determines whether a child could inherit sickle cell disease, a clinically important thalassemia, or another compound hemoglobin disorder.

  • Screening should assess both structural hemoglobin variants and reduced globin production.
  • Sickle cell trait is not sickle cell disease, but it can combine with HbS, HbC, HbE, or beta-thalassemia in a child.
  • Low MCV with normal iron studies can point toward thalassemia, even when hemoglobin electrophoresis looks normal.
  • Alpha-thalassemia risk depends on how many HBA1/HBA2 genes are altered and whether two-gene deletions are in cis or trans.
  • When one partner is a carrier, the other partner needs timely, appropriately matched testing.

Table of Contents

What the screen actually measures

Hemoglobin is built from globin chains. Adult hemoglobin A contains two alpha and two beta chains. The alpha chains are encoded by HBA1 and HBA2, with two alpha-globin genes on each chromosome 16 for a usual total of four. The beta chain is encoded by HBB on chromosome 11. Changes can alter the structure of a chain, reduce how much of it is made, or do both.

A well-designed carrier evaluation combines several layers:

Complete blood count: Hemoglobin concentration, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and red-cell count help identify microcytosis. Thalassemia carriers often have small red cells with a normal or relatively high red-cell count, but these patterns are not diagnostic by themselves.

Iron studies: Ferritin and other iron measures help separate iron deficiency from thalassemia. The two can coexist, so a low ferritin does not always end the evaluation.

Hemoglobin analysis: High-performance liquid chromatography, capillary electrophoresis, or another validated method quantifies hemoglobin fractions and identifies many structural variants. “Hemoglobin electrophoresis” is often used as a general label even when a different separation technology is used.

Molecular testing: DNA analysis may confirm an HBB variant, detect beta-thalassemia mutations, or evaluate HBA1/HBA2 deletions and nondeletional variants. Molecular testing is particularly important when alpha-thalassemia is suspected because many alpha carriers have a normal adult hemoglobin pattern.

The purpose is not merely to ask whether a person has HbS. It is to map the clinically relevant hemoglobin genotype well enough to understand reproductive combinations. Universal hemoglobinopathy testing before or early in pregnancy is increasingly recommended because self-identified race and ethnicity do not reliably identify everyone at risk.

Screening differs from diagnostic testing. A person with anemia, jaundice, pain episodes, splenomegaly, or an abnormal newborn screen needs a diagnostic evaluation. A healthy person planning pregnancy may begin with carrier screening. The same assays can overlap, but the clinical questions and urgency differ.

A broad carrier screening result should state the laboratory method, hemoglobin fractions, red-cell indices, DNA findings when performed, and the limitations that remain.

Sickle cell and other structural variants

The sickle variant is a specific HBB change that produces hemoglobin S. A person with one HbS allele and one usual beta-globin allele generally has sickle cell trait, commonly written HbAS. Most people with trait do not have the chronic anemia and vaso-occlusive complications of sickle cell disease. Trait can still matter in rare extreme conditions, and it is important for blood donation, family planning, and interpretation of some laboratory tests.

A typical HbAS pattern shows more HbA than HbS. Exact percentages vary with method, alpha-thalassemia, iron status, and other factors. A recent blood transfusion can make the pattern misleading because donor red cells contribute HbA.

Sickle cell disease is not limited to HbSS. Clinically important combinations include:

  • HbSS: two sickle alleles;
  • HbSC: one HbS allele and one HbC allele;
  • HbS/beta-zero thalassemia: HbS paired with an HBB variant that produces no beta-globin;
  • HbS/beta-plus thalassemia: HbS paired with an HBB variant that reduces beta-globin;
  • less common combinations involving other structural or thalassemia alleles.

This is why a partner who is “negative for sickle trait” may still be reproductively relevant if they carry HbC, HbE, beta-thalassemia, or another HBB variant. A focused sickle cell genetic test can clarify HBB findings when protein analysis is ambiguous.

HbC trait usually causes no major illness but can combine with HbS to cause HbSC disease. HbE trait is common in parts of Southeast Asia and is often mild by itself; HbE can combine with beta-thalassemia to produce a wide clinical spectrum. HbD, HbO-Arab, and other variants may be mistaken for one another on a single platform, so a second method or DNA confirmation may be needed.

Reports sometimes use a pattern rather than a definitive genotype, such as “variant in the S window.” That wording means the laboratory observed a peak that migrates like HbS but may require confirmation. Solubility tests alone are not sufficient for comprehensive carrier screening because they do not quantify fractions or identify many alternative variants.

A positive structural-variant result should answer three questions: what hemoglobin is present, whether the person has trait or disease, and which partner findings could create disease in a child. The answer depends on the full hemoglobin profile, not on one letter in isolation.

Beta-thalassemia results

Beta-thalassemia results from HBB variants that reduce or stop beta-globin production. A beta-zero allele produces essentially no beta-globin from that copy; a beta-plus allele permits some production. Hundreds of HBB variants exist, including substitutions, splice changes, promoter variants, small insertions or deletions, and less common larger rearrangements.

A classic beta-thalassemia carrier pattern includes:

  • low MCV and MCH;
  • normal or mildly reduced hemoglobin;
  • a relatively high red-cell count for the degree of microcytosis;
  • elevated HbA2, often with a small increase in HbF.

No single cutoff works in every circumstance. Iron deficiency, delta-globin variants, pregnancy, laboratory method, and particular HBB mutations can lower or alter HbA2. Some “silent” beta-thalassemia alleles cause only subtle changes. Conversely, an elevated HbA2 can have causes other than beta-thalassemia.

DNA testing is useful when the blood pattern is borderline, when a reproductive partner carries HbS or another HBB variant, or when a familial mutation is known. It can distinguish beta-zero from beta-plus alleles and identify variants that protein analysis cannot name confidently.

One pathogenic HBB variant consistent with reduced beta-globin generally indicates beta-thalassemia trait. Two clinically important HBB variants may cause beta-thalassemia intermedia or transfusion-dependent beta-thalassemia, but severity is modified by the exact alleles, fetal-hemoglobin modifiers, alpha-globin copy number, and other factors. Genotype informs counseling without providing a perfect forecast.

The phrase “thalassemia minor” is commonly used for carrier status. It does not mean that the DNA finding is temporary or that it will progress into “major.” Carriers may have lifelong microcytosis and mild anemia, but they do not develop transfusion-dependent beta-thalassemia simply because they age.

Iron should not be prescribed indefinitely just because the MCV is low. A carrier can also become iron deficient, but supplementation should be guided by iron studies. Repeatedly treating genetically determined microcytosis as iron deficiency can cause confusion and, in some circumstances, excessive iron exposure.

For a molecular result, confirm that the report distinguishes pathogenic variants from a VUS. A VUS should not be treated as a proven reproductive-risk allele without supporting hematologic, family, and laboratory evidence. More detailed interpretation is available in a beta-thalassemia HBB result guide.

Alpha-thalassemia results

Alpha-thalassemia is structurally different from beta-thalassemia because most people have four alpha-globin genes. Risk depends on how many are deleted or inactivated and how the changes are arranged.

A useful shorthand is:

  • αα/αα: four working genes;
  • -α/αα: one affected gene, often called a silent carrier;
  • –/αα or -α/-α: two affected genes, called alpha-thalassemia trait;
  • –/-α: three affected genes, usually hemoglobin H disease;
  • –/–: four affected genes, usually hemoglobin Bart hydrops fetalis syndrome.

The arrangement of two affected genes is crucial. A cis deletion places both missing genes on the same chromosome, written –/αα. A trans arrangement places one deletion on each chromosome, written -α/-α. Both can produce similar mild microcytosis in the carrier, but they create different fetal risks.

When two people each carry a cis two-gene deletion, a pregnancy can inherit both — chromosomes and have all four alpha genes deleted. This can cause severe fetal anemia, hydrops, maternal complications, and without specialized intervention is often lethal. When both parents have trans single-gene deletions, their children are not expected to inherit a four-gene deletion from that pairing, although other combinations can still matter.

Standard hemoglobin electrophoresis can be normal in alpha-thalassemia carriers. Low MCV with normal iron and no beta-thalassemia pattern should therefore prompt alpha-globin evaluation when clinically appropriate. Molecular testing usually needs deletion analysis because common alpha-thalassemia alleles are deletions. Sequencing may be added for nondeletional variants such as hemoglobin Constant Spring or when deletion testing does not explain the phenotype.

Nondeletional alpha variants can be more clinically consequential than a simple one-gene deletion. For example, a nondeletional allele paired with a two-gene cis deletion may cause a more severe hemoglobin H phenotype. The report should therefore name the exact HBA1/HBA2 finding rather than merely saying “alpha-thalassemia positive.”

Some laboratories cannot determine cis versus trans from an isolated copy-number result. Parental studies, family testing, variant-specific methods, or ancestry-informed interpretation may help. Do not infer phase from ancestry alone. The alpha-thalassemia genetic test guide explains gene count and phase in more detail.

Combining two partners’ results

Hemoglobinopathy risk is a couple-level calculation. Each partner’s report must be interpreted separately and then combined.

When both partners carry clinically important variants in the same globin system, each pregnancy may have a 25% chance of inheriting both relevant alleles. The possible condition depends on the pairing. Examples include HbS with HbS, HbS with HbC, HbS with a beta-thalassemia allele, two beta-thalassemia alleles, or alpha-globin changes that together remove or inactivate three or four genes.

The simple “both carriers equals 25%” statement needs refinement in alpha-thalassemia because each person can carry changes involving one or two of four genes, and phase matters. It also needs refinement when one parent has a disease genotype rather than a carrier genotype. A person with sickle cell disease, for example, will pass an abnormal HBB allele to every child, while the child’s final genotype depends on the other parent.

Partner testing should be matched to the first finding:

  • If one person has HbS trait, the partner needs a complete hemoglobinopathy evaluation, not only an HbS solubility test.
  • If one person has beta-thalassemia trait, the partner needs red-cell indices and hemoglobin analysis, with HBB molecular testing when indicated.
  • If one person has a cis alpha-zero deletion, the partner needs alpha-globin deletion and relevant nondeletional analysis, even if electrophoresis is normal.
  • If the first result is uncertain, a genetics or hematology professional should clarify it before labeling the couple high risk.

Sequential testing is efficient before pregnancy, but it can create delays during pregnancy. When gestational age matters, simultaneous testing or rapid partner evaluation may be appropriate. A negative partner result lowers risk but leaves residual risk from variants the assay cannot detect. The laboratory’s detection range and the partner’s blood indices help define how reassuring the result is.

An autosomal recessive partner-risk explanation can help with the basic inheritance arithmetic, but hemoglobinopathies require the additional protein and phase details described here.

Factors that can confuse testing

Several common circumstances can make a hemoglobinopathy report look simpler or stranger than it really is.

Recent transfusion

Donor red cells can change the measured percentages for weeks to months. A person with HbS may appear to have substantial HbA after transfusion. The ordering clinician should give the transfusion date to the laboratory. DNA testing may be preferable when an urgent genotype is needed, although stem-cell transplantation and donor-derived blood cells create separate specimen issues.

Iron deficiency

Iron deficiency lowers MCV and can coexist with alpha- or beta-thalassemia. It may reduce HbA2 enough to obscure some beta-thalassemia carrier patterns. Correcting iron deficiency and repeating selected testing may be useful when results are borderline.

Pregnancy and age

Hemoglobin fractions can shift during pregnancy. Newborns naturally have high HbF, so newborn-screen patterns use a different order and interpretation from adult reports. A newborn result such as “FS” or “FSA” requires confirmatory testing and cannot be read like adult electrophoresis.

Multiple inherited traits

A person may carry alpha-thalassemia plus HbS, HbE plus alpha-thalassemia, or another combination. Alpha-thalassemia can lower the percentage of some beta-chain variants and change red-cell indices. The traits do not cancel one another; they modify the laboratory pattern and sometimes the phenotype.

Method limitations

Two variants can migrate together on one platform. HPLC retention windows are clues, not always final identities. Some assays do not detect unstable hemoglobins well, and routine sequencing may miss large deletions or regulatory changes. A second protein method or molecular confirmation may be necessary.

Incomplete records

A verbal family history of “anemia,” “trait,” or “thalassemia” is not enough to select targeted testing. Obtain the relative’s actual report when possible. “Sickle trait” and “sickle beta-thalassemia” have very different implications.

VUS and incidental findings

Broad gene panels can find uncertain variants that do not explain the blood pattern. The best interpretation integrates the molecular result with MCV, MCH, HbA2, HbF, and the family’s segregation pattern. A DNA result should not override contradictory hematology without review.

Pregnancy and family planning

Couples with a meaningful chance of an affected pregnancy can discuss several options with a genetic counselor, maternal-fetal medicine specialist, or hematologist.

Prenatal diagnosis: Chorionic villus sampling or amniocentesis can test the fetus for known familial HBB or HBA variants. The laboratory needs precise parental genotypes. General cell-free DNA screening is not a substitute for standard diagnostic testing, although single-gene screening technologies continue to evolve.

IVF with PGT-M: Preimplantation genetic testing for monogenic disease can identify embryos at low or high risk for the familial hemoglobin genotype before transfer. Test development may require parental samples and sometimes relatives. Prenatal confirmation is commonly discussed because PGT-M analyzes a small embryo biopsy and has technical limits.

Donor gametes, donor embryos, adoption, or conception without testing: Values, access, cost, beliefs, timing, and expected disease severity all influence decisions. Counseling should provide options without directing the couple toward one choice.

For a pregnancy at risk for alpha-thalassemia major, early specialist care matters because the fetus and pregnant patient can develop serious complications. Specialized centers may discuss fetal surveillance, intrauterine transfusion, or other management. For a fetus diagnosed with sickle cell disease or beta-thalassemia, prenatal diagnosis allows time for pediatric hematology planning, newborn prophylaxis, and family support.

Carrier status also has implications beyond reproduction. Sickle trait should be recorded in the medical chart. Beta- or alpha-thalassemia trait can prevent repeated workups for lifelong microcytosis. Relatives may benefit from testing, especially siblings and adult children planning families.

Do not test a child solely because a parent is a carrier without considering whether the result has current medical value. Newborn screening already assesses many clinically significant hemoglobin patterns, but state or national programs differ and may not fully define alpha-thalassemia carrier status. Keeping parental reports makes future interpretation easier.

A practical result review

Read the report in a fixed sequence:

  1. Confirm the specimen and timing. Was the person recently transfused, pregnant, or a newborn?
  2. Review CBC and iron status. Is MCV low, and is iron deficiency present?
  3. List each hemoglobin fraction. Note HbA, HbA2, HbF, and any variant peaks with percentages.
  4. Read the molecular findings. Identify the gene, exact variant or deletion, zygosity, and classification.
  5. Determine the person’s state. Is this carrier status, disease, an uncertain pattern, or a result requiring confirmation?
  6. Assess phase and gene count. This is especially important for alpha-thalassemia and for two molecular findings.
  7. Match the partner test. Make sure it can detect the combinations that matter.
  8. Calculate pregnancy risk. Use the exact parental genotypes, not a generic ancestry statistic.
  9. Plan confirmatory or reproductive steps. Consider hematology, genetics, prenatal diagnosis, or PGT-M as appropriate.

A negative report should state what was tested. A normal electrophoresis does not exclude alpha-thalassemia. A negative HBB sequence test does not exclude all large deletions. A normal MCV makes many thalassemia carrier states less likely but does not exclude every mild or silent allele.

Common errors include calling all microcytosis iron deficiency, describing sickle trait as a mild form of sickle cell disease, overlooking HbC or beta-thalassemia in the partner, and ignoring alpha-globin phase. Another is assuming that two “traits” can only produce a trait. Two different HBB traits can combine into a clinically important disease.

Seek prompt medical evaluation for severe anemia, breathing difficulty, chest pain, neurologic symptoms, jaundice with illness, splenic enlargement or pain, or a newborn with an abnormal screen. Carrier screening is primarily preventive and reproductive, but an unexpected pattern can reveal a person who needs diagnostic care now.

References

Disclaimer

This article is educational and does not replace medical diagnosis, hematology care, genetic counseling, or prenatal advice. Interpretation depends on the complete blood count, iron status, hemoglobin fractions, molecular method, transfusion history, pregnancy status, and both partners’ exact results. Review abnormal, uncertain, or discordant findings with a qualified clinician before making treatment or reproductive decisions.

RELATED ARTICLESMORE FROM AUTHOR